MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318883 | Name: Tolazamide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tolazamide is an oral blood glucose lowering drug used for people with Type 2 diabetes. It is part of the sulfonylurea family (ATC A10BB).

Chemical Structure

Tolazamide
CAS#1156-19-0

Theoretical Analysis

MedKoo Cat#: 318883

Name: Tolazamide

CAS#: 1156-19-0

Chemical Formula: C14H21N3O3S

Exact Mass: 311.1304

Molecular Weight: 311.40

Elemental Analysis: C, 54.00; H, 6.80; N, 13.49; O, 15.41; S, 10.30

Price and Availability

Size Price Availability Quantity
100mg USD 650.00 2 Weeks
200mg USD 1,000.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Tolazamide, Tolinase, Norglycin, Tolanase, Tolazolamide
IUPAC/Chemical Name
1-(azepan-1-yl)-3-(4-methylphenyl)sulfonylurea
InChi Key
OUDSBRTVNLOZBN-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H21N3O3S/c1-12-6-8-13(9-7-12)21(19,20)16-14(18)15-17-10-4-2-3-5-11-17/h6-9H,2-5,10-11H2,1H3,(H2,15,16,18)
SMILES Code
O=C(NS(=O)(C1=CC=C(C)C=C1)=O)NN2CCCCCC2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 311.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Jannetto PJ, Langman LJ. Analysis of Hypoglycemic Drugs by Liquid Chromatography-Tandem Mass Spectrometry. Methods Mol Biol. 2024;2737:297-306. doi: 10.1007/978-1-0716-3541-4_27. PMID: 38036831. 2: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Tolazamide. 2023 Sep 15. PMID: 30000177. 3: Zhang J, Li MN, Yang GM, Hou XT, Yang D, Han MM, Zhang Y, Liu YF. Effects of water-sodium balance and regulation of electrolytes associated with antidiabetic drugs. Eur Rev Med Pharmacol Sci. 2023 Jun;27(12):5784-5794. doi: 10.26355/eurrev_202306_32817. PMID: 37401315. 4: Wang S, Wang R, Xu N, Wei X, Yang Y, Lian Z, Cen B, Shen C, Li W, Wang J, Zhang Z, Tang L, Wei Q, Lu D, Xu X. SULT2B1-CS-DOCK2 axis regulates effector T-cell exhaustion in HCC microenvironment. Hepatology. 2023 Oct 1;78(4):1064-1078. doi: 10.1097/HEP.0000000000000025. Epub 2023 Jan 3. PMID: 36626623. 5: Rodriguez EL, Tao P, Woolfork AG, Li Z, Matsuda R, Sun Z, Hage DS. Studies of binding by sulfonylureas with glyoxal- and methylglyoxal-modified albumin by immunoextraction using affinity microcolumns. J Chromatogr A. 2021 Feb 8;1638:461683. doi: 10.1016/j.chroma.2020.461683. Epub 2020 Nov 10. PMID: 33223150; PMCID: PMC7870548. 6: Feng Z, Chen M, Xue Y, Liang T, Chen H, Zhou Y, Nolin TD, Smith RB, Xie XQ. MCCS: a novel recognition pattern-based method for fast track discovery of anti- SARS-CoV-2 drugs. Brief Bioinform. 2021 Mar 22;22(2):946-962. doi: 10.1093/bib/bbaa260. PMID: 33078827; PMCID: PMC7665328. 7: Hendriks AM, Schrijnders D, Kleefstra N, de Vries EGE, Bilo HJG, Jalving M, Landman GWD. Sulfonylurea derivatives and cancer, friend or foe? Eur J Pharmacol. 2019 Oct 15;861:172598. doi: 10.1016/j.ejphar.2019.172598. Epub 2019 Aug 10. PMID: 31408647. 8: Fedorov AY, Rychkov DA, Losev EA, Drebushchak TN, Boldyreva EV. Completing the picture of tolazamide polymorphism under extreme conditions: a low- temperature study. Acta Crystallogr C Struct Chem. 2019 May 1;75(Pt 5):598-608. doi: 10.1107/S2053229619005217. Epub 2019 Apr 29. PMID: 31062718. 9: Tao P, Li Z, Woolfork AG, Hage DS. Characterization of tolazamide binding with glycated and normal human serum albumin by using high-performance affinity chromatography. J Pharm Biomed Anal. 2019 Mar 20;166:273-280. doi: 10.1016/j.jpba.2019.01.025. Epub 2019 Jan 14. PMID: 30682693; PMCID: PMC6382535. 10: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Sulfonylureas, First Generation. 2018 Mar 16. PMID: 31644148. 11: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Sulfonylureas. 2018 Mar 16. PMID: 31643682. 12: Vos RC, van Avendonk MJ, Jansen H, Goudswaard AN, van den Donk M, Gorter K, Kerssen A, Rutten GE. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control. Cochrane Database Syst Rev. 2016 Sep 18;9(9):CD006992. doi: 10.1002/14651858.CD006992.pub2. PMID: 27640062; PMCID: PMC6457595. 13: Boldyreva EV, Arkhipov SG, Drebushchak TN, Drebushchak VA, Losev EA, Matvienko AA, Minkov VS, Rychkov DA, Seryotkin YV, Stare J, Zakharov BA. Isoenergetic Polymorphism: The Puzzle of Tolazamide as a Case Study. Chemistry. 2015 Oct 19;21(43):15395-404. doi: 10.1002/chem.201501541. Epub 2015 Sep 4. PMID: 26337712. 14: Srivastava P, Tiwari A, Trivedi AC, Thakur V, Pant AB, Saxena S. Virtual Screening of Natural and Synthetic Ligands Against Diabetic Retinopathy by Molecular Interaction With Angiopoietin-2. Asia Pac J Ophthalmol (Phila). 2014 Jul-Aug;3(4):257-9. doi: 10.1097/APO.0000000000000071. PMID: 26107766. 15: Gao Y, Olsen KW. Drug-polymer interactions at water-crystal interfaces and implications for crystallization inhibition: molecular dynamics simulations of amphiphilic block copolymer interactions with tolazamide crystals. J Pharm Sci. 2015 Jul;104(7):2132-41. doi: 10.1002/jps.24442. Epub 2015 Jun 4. PMID: 26045147. 16: Sharma N, Sim YB, Park SH, Lim SM, Kim SS, Jung JS, Hong JS, Suh HW. Effect of sulfonylureas administered centrally on the blood glucose level in immobilization stress model. Korean J Physiol Pharmacol. 2015 May;19(3):197-202. doi: 10.4196/kjpp.2015.19.3.197. Epub 2015 Apr 30. PMID: 25954123; PMCID: PMC4422958. 17: Granberry MC, Fonseca VA. Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. Am J Cardiovasc Drugs. 2005;5(3):201-9. doi: 10.2165/00129784-200505030-00006. PMID: 15901207. 18: Biederman JI, Vera E, Rankhaniya R, Hassett C, Giannico G, Yee J, Cortes P. Effects of sulfonylureas, alpha-endosulfine counterparts, on glomerulosclerosis in type 1 and type 2 models of diabetes. Kidney Int. 2005 Feb;67(2):554-65. doi: 10.1111/j.1523-1755.2005.67112.x. Erratum in: Kidney Int. 2005 Mar;67(3):1213. PMID: 15673303. 19: Ho EN, Yiu KC, Wan TS, Stewart BD, Watkins KL. Detection of anti-diabetics in equine plasma and urine by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Nov 5;811(1):65-73. doi: 10.1016/j.jchromb.2004.03.070. PMID: 15458724. 20: Ozawa H, Murai Y, Ozawa T. [A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus]. Yakushigaku Zasshi. 2003;38(1):11-27. Japanese. PMID: 14570054.

View History

Liquiritin apioside

Liquiritin apioside

MET-IN-3S

MET-IN-3S

CDNG1

CDNG1

Nitroquine

Nitroquine

Tetulomab tetraxetan Lu-177

Tetulomab tetraxetan Lu-177

Nitrosobaygon

Nitrosobaygon